Sznol M - Search Results

1

Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial.

Kluger HM, Chiang V, Mahajan A, Zito CR, Sznol M, Tran T, Weiss SA, Cohen JV, Yu J, Hegde U, Perrotti E, Anderson G, Ralabate A, Kluger Y, Wei W, Goldberg SB, Jilaveanu LB. Kluger HM, et al. Among authors: sznol m. J Clin Oncol. 2019 Jan 1;37(1):52-60. doi: 10.1200/JCO.18.00204. Epub 2018 Nov 8. J Clin Oncol. 2019. PMID: 30407895 Free PMC article. Clinical Trial.

2

A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma.

Dutcher JP, Gaynor ER, Boldt DH, Doroshow JH, Bar MH, Sznol M, Mier J, Sparano J, Fisher RI, Weiss G, et al. Dutcher JP, et al. Among authors: sznol m. J Clin Oncol. 1991 Apr;9(4):641-8. doi: 10.1200/JCO.1991.9.4.641. J Clin Oncol. 1991. PMID: 2066760 Clinical Trial.

3

Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study.

Parkinson DR, Abrams JS, Wiernik PH, Rayner AA, Margolin KA, Van Echo DA, Sznol M, Dutcher JP, Aronson FR, Doroshow JH, et al. Parkinson DR, et al. Among authors: sznol m. J Clin Oncol. 1990 Oct;8(10):1650-6. doi: 10.1200/JCO.1990.8.10.1650. J Clin Oncol. 1990. PMID: 2213101 Clinical Trial.

4

Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells.

Bar MH, Sznol M, Atkins MB, Ciobanu N, Micetich KC, Boldt DH, Margolin KA, Aronson FR, Rayner AA, Hawkins MJ, et al. Bar MH, et al. Among authors: sznol m. J Clin Oncol. 1990 Jul;8(7):1138-47. doi: 10.1200/JCO.1990.8.7.1138. J Clin Oncol. 1990. PMID: 2358835

5

Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma.

Sparano JA, Fisher RI, Sunderland M, Margolin K, Ernest ML, Sznol M, Atkins MB, Dutcher JP, Micetich KC, Weiss GR, et al. Sparano JA, et al. Among authors: sznol m. J Clin Oncol. 1993 Oct;11(10):1969-77. doi: 10.1200/JCO.1993.11.10.1969. J Clin Oncol. 1993. PMID: 8410122 Clinical Trial.

6

Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.

Gause BL, Sznol M, Kopp WC, Janik JE, Smith JW 2nd, Steis RG, Urba WJ, Sharfman W, Fenton RG, Creekmore SP, Holmlund J, Conlon KC, VanderMolen LA, Longo DL. Gause BL, et al. Among authors: sznol m. J Clin Oncol. 1996 Aug;14(8):2234-41. doi: 10.1200/JCO.1996.14.8.2234. J Clin Oncol. 1996. PMID: 8708712 Clinical Trial.

7

Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer.

Curti BD, Ochoa AC, Powers GC, Kopp WC, Alvord WG, Janik JE, Gause BL, Dunn B, Kopreski MS, Fenton R, Zea A, Dansky-Ullmann C, Strobl S, Harvey L, Nelson E, Sznol M, Longo DL. Curti BD, et al. Among authors: sznol m. J Clin Oncol. 1998 Aug;16(8):2752-60. doi: 10.1200/JCO.1998.16.8.2752. J Clin Oncol. 1998. PMID: 9704728 Clinical Trial.

8

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.

Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA. Atkins MB, et al. Among authors: sznol m. J Clin Oncol. 1999 Jul;17(7):2105-16. doi: 10.1200/JCO.1999.17.7.2105. J Clin Oncol. 1999. PMID: 10561265 Review.

9

Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma.

Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber DJ, Sherry RM, Topalian SL, Yang JC, Stock F, Freezer LJ, Morton KE, Seipp C, Haworth L, Mavroukakis S, White D, MacDonald S, Mao J, Sznol M, Rosenberg SA. Toso JF, et al. Among authors: sznol m. J Clin Oncol. 2002 Jan 1;20(1):142-52. doi: 10.1200/JCO.2002.20.1.142. J Clin Oncol. 2002. PMID: 11773163 Free PMC article. Clinical Trial.

10

Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.

Murren J, Modiano M, Clairmont C, Lambert P, Savaraj N, Doyle T, Sznol M. Murren J, et al. Among authors: sznol m. Clin Cancer Res. 2003 Sep 15;9(11):4092-100. Clin Cancer Res. 2003. PMID: 14519631 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

245 results

Search Page

Filters